Activating Nrf2 mutations have been described in lung cancer, liver cancer, ovarian cancer, head and neck cancer, kidney cancer, breast cancer, and esophageal cancer, but loss-of-function mutations in KEAP1 and CUL3 also occur frequently [58,59,60,61,62]. Here, KEAP1 is linked to ovarian carcinoma.